Citalopram HEXAL is a supportive therapeutic option commonly used across key psychiatric domains where symptoms are moderate-to-severe and significantly disrupt daily stability. It is often applied in contexts requiring long-term management, relevant when supportive symptom management is appropriate for long-term stability.

The medication is used for managing the symptoms of conditions such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD). It helps address core symptom clusters like persistent depressed mood, excessive, uncontrollable worry, and intrusive thoughts.

“The primary benefit is that it may assist with managing symptoms related to persistent low mood and anxiety, helping to maintain a sense of stability.”

This provides support that helps ease the overall symptom burden in patients experiencing chronic apprehension, contributing to improved comfort during symptomatic periods.

---

Quick Fact: Relief for Anxiety and Mood Symptoms
Citalopram HEXAL is commonly used to help with patterns of emotional tension and distress that interfere with daily functioning, assisting with maintaining functional stability when symptoms are more noticeable.

---

Regulatory References

1. NIH MedlinePlus Drug Information

This section summarizes the official eligibility and non-eligibility requirements for Citalopram, strictly based on regulatory documentation from authorities like the FDA and EMA.

Contraindicated Use

Citalopram is contraindicated (must not be used) in patients with:

• Known Hypersensitivity to citalopram or any of its inactive ingredients.
• Concomitant MAOI Therapy: Use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue.
• Concomitant QT-Prolonging Drugs: Concurrent use with other medications known to prolong the QT interval, such as pimozide.
• Pre-existing Cardiac Conditions: Patients with congenital long QT syndrome, other conditions that prolong the QT interval, uncorrected hypokalemia (low potassium) or hypomagnesemia (low magnesium).

Restricted and Special Populations

Maximum dosage is officially restricted to 20 mg per day in several specific populations due to the increased risk of QT prolongation and altered drug clearance:

• Older Adults (typically over 60 years of age).
• Patients with Hepatic Impairment (liver disease).
• Patients who are known or suspected CYP2C19 poor metabolizers.

Age and Life Stage Eligibility

• Pediatric Patients (Under 18): Use is generally not approved for the primary indication, as safety and efficacy have not been established.
• Pregnancy and Lactation: Use during pregnancy, particularly the third trimester, is associated with documented risks (e.g., Persistent Pulmonary Hypertension of the Newborn). Citalopram passes into breast milk, requiring caution and monitoring of the infant.

Interactions with other medicines and products

Citalopram HEXAL (Escitalopram) has specific, officially documented interaction patterns that necessitate restrictions on co-administration, as mandated by regulatory authorities.

Contraindicated Combinations and Timing Rules

Co-administration is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including non-selective MAOIs, the antibiotic Linezolid, and Intravenous Methylene Blue, due to the high regulatory risk of Serotonin Syndrome. Co-administration with the antipsychotic drug Pimozide is also contraindicated due to the potential for additive effects resulting in QT interval prolongation. When discontinuing a psychiatric MAOI before starting Escitalopram, or vice versa, a 14-day washout period must elapse.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Escitalopram is a documented modest inhibitor of the CYP2D6 enzyme, which can lead to increased plasma exposure of drugs metabolized by CYP2D6 (e.g., Metoprolol). Conversely, the co-administration of CYP2C19 inhibitors (e.g., Omeprazole, Cimetidine) or CYP3A4 inhibitors may increase Escitalopram exposure by inhibiting its metabolic clearance. Furthermore, co-administration with other serotonergic agents (e.g., Triptans, St. John's Wort) increases the regulatory risk of Serotonin Syndrome (Pharmacodynamic interaction). Using the product with drugs affecting hemostasis (e.g., NSAIDs, Warfarin) increases the risk of abnormal bleeding.

Selective Inhibition of the Serotonin Transporter (SERT)

Escitalopram, the active component, exerts its primary action by selective reuptake inhibition of the Serotonin Transporter (SERT) protein in the brain. This molecular blockade immediately prevents the reabsorption of serotonin (5- HT) from the synaptic cleft, leading to an increased concentration of the neurotransmitter available to activate postsynaptic receptors.

Time-Dependent Neuroplastic Adaptation

The full physiological effect of the mechanism relies on slower, time-dependent neuroplastic changes that occur following the initial surge of synaptic serotonin. This includes the desensitization of 5-HT1 A autoreceptors, which removes an inhibitory brake on serotonin release. This physiological adaptation results in a sustained, increased functional flow of serotonergic signaling.

Functional Regulation of CNS Regulatory Circuits

The combined molecular action and subsequent neuroplastic adaptation result in the functional modulation of activity within the central nervous system pathways governing key regulatory circuits. This mechanism functionally regulates overactive or dysregulated serotonergic signaling, driving the long-term modulation of central regulatory circuits.

How to Use Citalopram HEXAL

Citalopram HEXAL is taken via the oral route of administration, consistent with its available forms as film-coated tablets or an oral solution. The tablets are supplied in strengths including 5 mg, 10 mg (scored), and 20 mg (scored), and the oral solution is concentrated at 1 mg per mL. Administration of the medicine is once daily, and it may be taken with or without food, providing flexibility in the daily schedule. Patients may administer the dose in the morning or evening.

---

Dosing Patterns and Adjustments

The standard adult regimen for treatment typically initiates with a dose of 10 mg once daily. This dose may be adjusted to a maximum of 20 mg per day, but dose increases are generally undertaken after a minimum interval of one week of treatment at the lower dose. Doses exceeding 20 mg have not consistently demonstrated additional benefit and are not generally recommended.

Specific adjustments to this regimen are defined for certain populations. For older adults (over 65 years of age) and those with hepatic impairment, the maximum recommended dose is typically restricted to 10 mg once daily. While no adjustment is necessary for mild to moderate renal impairment, caution is advised for patients with severe renal impairment. When treatment is to be concluded, a gradual dose reduction is the official procedural step recommended for stopping the medicine.

Research Evidence / Overview of Studies for Citalopram HEXAL

Research evidence for Citalopram HEXAL (Escitalopram) is based on studies that examine the drug's properties, the populations included, and areas that remain to be fully explored. Research described here is limited to the study structures and reported patterns, without making claims about individual outcomes or offering clinical advice.

---

Evidence for Use in Major Depressive Disorder (MDD)

The research landscape for MDD includes numerous short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults, focusing on outcomes related to symptom intensity. Findings describe patterns observed in these studies regarding the measured changes in symptom scores. Research examined whether the patterns observed differed when compared to placebo.

Additionally, meta-analyses have been conducted. These large analyses help contextualize how findings evolved in the observed populations, sometimes suggesting patterns that vary from those seen with other active comparators. Research also was studied for people with more severe symptom presentations, with some trials reporting distinct patterns in this subgroup.

---

Evidence for Use in Anxiety and Related Disorders

Research has also explored the use of Citalopram HEXAL in various anxiety-related conditions, typically through short-term RCTs. These studies monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level.

Evidence for Generalized Anxiety Disorder (GAD) and Panic Disorder

For Generalized Anxiety Disorder, short-term trials and follow-up maintenance studies were observed in adults. Studies monitored outcomes capturing phases of heightened symptom activity. Similar controlled trials were evaluated in Panic Disorder, with research examining the measured characteristics of acute episodes.

Evidence for Obsessive-Compulsive Disorder (OCD)

Specific studies were evaluated in adults with Obsessive-Compulsive Disorder, which is a condition characterized by fluctuating manifestations. Research exploring short-term symptom changes was conducted, but long-term evidence is limited regarding whether the observed changes apply consistently to all different symptom types of OCD.

---

Duration of Evidence: Outcomes over Extended Durations and Follow-up

Research has examined outcomes over extended durations through maintenance studies, where subjects who had an initial measured change continued treatment for extended periods. These studies monitored time until a return of symptoms. It is important to know that results apply only to the populations studied in these follow-up designs. For all conditions, information regarding measured changes over many years is not fully established, and certainty remains low regarding outcomes after a pre-defined study duration.

---

Understanding the Evidence Quality and Uncertainty

Research describes group patterns observed in studies; it does not determine whether an individual will respond similarly. While the evidence base is large, particularly for MDD and GAD, several limitations are noted:

• Insufficient Data for Certain Groups: Data for very young children or those with specific combinations of multiple conditions, remain insufficient.
• Uncertainty in Comparative Findings: In research scenarios involving active comparators, the data show patterns related to measured changes when Citalopram HEXAL was studied against certain other treatments; the findings were mixed.
• Limited Long-Term Information: As noted above, long-term effects are not fully established, and follow-up durations were limited in most initial short-term trials.

Key Studies & References Escitalopram MedlinePlus Drug Information

Common questions about Citalopram HEXAL (FAQ)

Q: What is the half-life of Escitalopram and how long does it stay in my system?

The terminal elimination half-life of Escitalopram, according to official product information, is reported to be approximately 27 to 32 hours. The half-life is a measure of the time it takes for half of the drug to be cleared from the body. This measure is a pharmacokinetic characteristic used by healthcare professionals to guide appropriate prescribing.

Q: Will escitalopram affect my blood pressure or heart rate?

Official warnings note that caution is advised for individuals with pre-existing heart issues. Escitalopram has the potential to cause changes in the heart's electrical rhythm, such as an irregular heartbeat or a change in heart rate (which could include a faster or lower heart rate). Official product documents detail specific cardiac conditions that contraindicate its use.

Q: Does escitalopram cause weight gain or changes in appetite?

Official reports indicate that changes in appetite and weight have been reported as possible effects. This can include either a decreased appetite resulting in weight loss, or in some cases, weight gain. Official documents state that the weight and growth of children and adolescents should be monitored.

Q: Is it safe to drive or operate heavy machinery while taking escitalopram?

The official product monographes caution that, like all psychoactive medicines, Citalopram HEXAL may potentially impair judgment, thinking, or motor skills. This means that a potential risk to the ability to drive a car or operate machinery must be considered. This is a general regulatory statement issued to ensure patient awareness.

Q: Will escitalopram affect my blood sugar levels or diabetes management?

Official patient information suggests that for individuals with diabetes, Citalopram HEXAL may make it more challenging to maintain stable blood sugar levels. Regulatory documents note that caution is advised when the medicine is used alongside insulin or other diabetes medications. There is a potential risk of low blood sugar, which is medically known as hypoglycemia.

Q: Can escitalopram cause problems with my vision?

Several visual changes have been reported in official documents, including temporary blurred vision and disturbances in the eye's ability to focus (abnormal accommodation). Eye pain and general visual disturbance have also been noted in clinical reports. A rare, serious ocular condition known as angle-closure glaucoma has been reported in post-marketing surveillance.

Q: Does escitalopram cause increased sensitivity to the sun (photosensitivity)?

A reaction known as photosensitivity, which is an increased sensitivity to sunlight, has been reported as a rare side effect in regulatory documentation. This is noted as the skin may be more susceptible to sunburn or rash when exposed to the sun. Official patient information provides this warning.

Q: Is escitalopram addictive or can I become dependent on it?

Escitalopram is generally considered non-addictive in clinical and regulatory literature. However, official safety authorities emphasize that abruptly stopping the medicine can lead to unpleasant physical and emotional withdrawal symptoms. For this reason, a gradual dose reduction (tapering) is officially recommended by health authorities for discontinuing the medication.

Q: Does escitalopram cause vivid dreams?

Vivid dreams are a reported symptom which may be noted by some users while taking the medicine. Official safety information indicates that this can sometimes be a manifestation of a discontinuation syndrome if the medication is stopped suddenly without the recommended gradual dose reduction.

How to Store and Dispose of Citalopram (Escitalopram)

Citalopram (Escitalopram) must be stored according to regulatory requirements to ensure its stability. Tablets should be stored at Controlled Room Temperature (20° to 25°C) or not above 25 C or 30 C, depending on the specific label, and kept in their original container. It is mandatory to keep the medicine out of the sight and reach of children.

---

Stability and Disposal

The Citalopram oral solution has a stability limit, requiring any remainder to be discarded 16 weeks after the bottle is first opened. Unused or expired medication must not be thrown into household waste or flushed down the toilet. Disposal should be completed through a medicine take-back program or by returning the product to a pharmacist, following local pharmaceutical waste guidelines.